56 articles in this topic
A clinical account of the nutrient-sensing trade-off — what actually induces cellular clean-up in humans rather than in mice, why muscle wins the argument in an older patient, and where the rapamycin and metformin evidence genuinely stops.
What a senescent cell is, how a small population drives systemic inflammation, and an honest account of senolytic human data — early-phase, mechanistic, and short of any outcome a patient cares about.
A deep mechanistic dive into the signaling cascades, epigenetic reprogramming, and translational science behind parabiosis — from GDF11 controversies to clinical plasma trials.
A clinical guide to protein and metabolite measurement — why these layers report present state rather than inherited risk, what broad panels can and cannot support, and how to judge an organ-age or metabolomic result you did not order.
A deep mechanistic investigation into how rapamycin and next-generation rapalogs modulate aging pathways — from allosteric binding kinetics to clinical trial design and emerging bi-steric inhibitors.
A clinical guide to interpreting biological-age and pace-of-aging results: what the epigenome is, what each generation of clock was trained to predict, why repeat testing of the same sample can differ by years, and how to counsel a patient who wants to buy one.
The fourth-tier hallmarks — regenerative decline, altered tissue signaling, inflammaging and gut dysbiosis — are the ones that actually walk into clinic. How to measure them with a dynamometer, a hallway and a short lab panel, and which single prescription moves several at once.
The three aging processes that begin as protective responses and become drivers — what can actually be measured in clinic today, and where the human evidence for rapamycin, metformin, NAD precursors and senolytics genuinely stands.
A clinical read of the five upstream hallmarks — genomic instability, telomere attrition, epigenetic drift, loss of proteostasis and disabled autophagy — separating what is measurable in a patient from what is mechanism only, and what has human endpoint data from what does not.
Master the cutting-edge molecular science of TGF-β-driven fibrosis — from epigenetic reprogramming and mechanotransduction to next-generation therapeutic strategies targeting specific pathway nodes in aging tissue.
A sequenced account of the advanced longevity workup — genome, blood, imaging, function, microbiome, proteomics, liquid biopsy — with a stated confidence on every element and a method for turning fifty abnormal values into one first action.
Explore the advanced molecular architecture of purinergic stress signaling — from transcriptional reprogramming and metabolic crosstalk to emerging therapeutic strategies targeting CD38, P2X7, and the ectonucleotidase axis in aging.
